Entering text into the input field will update the search result below

Recursion falls after delay for GM2 gangliosidosis trial

Mar. 03, 2022 3:48 PM ETRecursion Pharmaceuticals, Inc. (RXRX)By: Dulan Lokuwithana, SA News Editor
  • The shares of the clinical-stage biotechnology company Recursion Pharmaceuticals (RXRX -10.2%) are set to close at an all-time low on Thursday after the company announced a delay for its Phase 2 trial for REC-3599 in rare genetic disorder, infantile GM2 gangliosidosis (GM).

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About RXRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Recursion Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc.
POINT Biopharma Global Inc.
Catalyst Pharmaceuticals, Inc.
Merus N.V.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.